| Literature DB >> 2279462 |
Abstract
Brain and plasma concentrations of oxaminiquine were determined following intravenous dosing (15 mg kg-1) in female Wistar rats. Maximum brain concentrations were achieved one hour after dosing and at all sampling times oxamniquine levels were higher in brain tissues compared to the corresponding plasma samples. It is concluded that the reported adverse neurological effects associated with the clinical use of oxaminiquine in man may be due to the passage of sufficiently large quantities of this drug into the CNS.Entities:
Mesh:
Substances:
Year: 1990 PMID: 2279462 DOI: 10.3109/01480549009032291
Source DB: PubMed Journal: Drug Chem Toxicol ISSN: 0148-0545 Impact factor: 3.356